Uncovering immunogenomic drivers of acquired resistance to immunotherapy in a real-world pan-cancer setting

Learn how AstraZeneca partnered with Tempus to analyze a large-scale, multimodal dataset, identifying novel molecular drivers of acquired immunotherapy resistance to inform future therapeutic development.

Jun 02, 2026
Life Sciences
Case Study

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Bridging the gap: How Target Trial Emulation transforms real-world data into credible evidence

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital background with glowing white lines and a fading dotted pattern.

Q&A: Predicting response and resistance in ADCs with AI and multimodal data

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract background with light grey gradient, digital dots, and subtle wave patterns.

Researchers across pharma and academia are reducing oncology drug timelines with Tempus Lens

2026-08-12
Life Sciences